Sorrento Therapeutics, Inc.
SRNE
$0.0009
-$0.0001-10.00%
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Net Income | -548.00M | -671.64M | -572.84M | -493.57M | -523.79M |
| Total Depreciation and Amortization | 13.93M | 13.57M | 13.25M | 12.75M | 12.94M |
| Total Amortization of Deferred Charges | 5.25M | 5.25M | -- | -- | -- |
| Total Other Non-Cash Items | 161.63M | 288.04M | 196.19M | 148.58M | 197.08M |
| Change in Net Operating Assets | 132.56M | 104.82M | 69.55M | 34.58M | -5.83M |
| Cash from Operations | -234.63M | -259.96M | -293.86M | -297.66M | -319.60M |
| Capital Expenditure | -8.59M | -11.15M | -13.66M | -11.34M | -8.68M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 3.55M | 4.53M | -6.54M | 20.29M | 2.18M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -6.55M | -6.55M | -8.32M | -34.64M | -5.70M |
| Cash from Investing | -11.58M | -13.17M | -28.52M | -25.69M | -12.20M |
| Total Debt Issued | 160.34M | 84.11M | 99.45M | 113.25M | 84.38M |
| Total Debt Repaid | -82.26M | -143.55M | -188.31M | -165.73M | -140.02M |
| Issuance of Common Stock | 157.12M | 261.94M | 403.53M | 409.97M | 381.70M |
| Repurchase of Common Stock | -1.44M | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -11.00K | -- | -- | -- | -- |
| Other Financing Activities | 12.84M | -2.95M | -2.95M | -- | -- |
| Cash from Financing | 246.59M | 199.55M | 311.72M | 357.50M | 326.06M |
| Foreign Exchange rate Adjustments | -974.00K | -670.00K | -2.37M | -3.20M | -1.21M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -596.00K | -74.25M | -13.03M | 30.95M | -6.95M |